Indoco Remedies Limited is a Public Limited Company domiciled in India and incorporated under the provision of the Companies Act, VII of 1913. Its Shares are listed on two stock exchanges in India i.e Bombay Stock Exchange and National Stock Exchange. The company has decades of presence in the Indian Pharma market and a strong foothold in the international market.
Indoco has strengthened its wings in the international markets and offers complete solutions, including product development, manufacture and supply of Finished Dosages, APIs and Intermediates to generic companies worldwide. The company has a large basket of products backed by ANDAs / eCTD Dossiers and Drug Master Files (DMFs).
Expertise in Research & Development, backward integration in API in select products, own CRO set-up, excellence in Finished Dosages manufacturing and a strong customer base will ensure consistent growth in the Company’s Domestic, as well as International business.
Business area of the company
Indoco Remedies is engaged in the manufacturing and marketing of Formulations (Finished Dosage Forms) and Active Pharmaceutical Ingredients (APIs). The Company caters to both domestic and International markets.
Awards and Accolades
Patent Award
Indoco awarded with the IDMA Formulations Best Patent Award 2018-19 for 2 formulation patents - Diclofenac & Quetiapine
Indoco wins the IDMA Formulations Patent Award 2017-18 for 1 International and 2 Indian patents -Olopatadine, Gliclazide & Brinzolamide Ophthalmic Solution
Indoco receives the 'IDMA Best Patent Award' for four API Process Patents in 2017
Indoco Honoured with the 'IDMA Best Patent Award' for Three International Patents in 2016
Indoco honoured with the 'Best Patent Award' by PHARMEXCIL in the Bulk Drugs / API category in 2016
Indoco receives European Patent approval for Lacosamide
Indoco honoured with 'Certificate of Appreciation' (Bulk Drugs) in 2015
Indoco wins 'Patent Appreciation Award' at 52nd IDMA Award Function in 2014
Awards
Rajhans Pratisthan Award 2017 for Mr. Suresh G. Kare and Indoco for commendable CSR initiatives carried out under the banner 'SUMATI SANGOPAN'
Mr. Suresh G. Kare receives 'The Pride of Goa' Award 2016 by the Goa Chamber of Commerce & Industry
Mr. Suresh G. Kare honoured with 'Lifetime Achievement Award' at the hands of The Chief Minister of Goa in 2016
Mr. Suresh G. Kare honoured with Udyogshree Life Time Achievement Award by Hon'ble Defence Minister, Mr. Manohar Parrikar in 2013
Mr. Suresh G. Kare received the prestigious Excellence Award-2004 from Pharma Business And Technology.
Ms. Aditi Kare Panandikar receives the 'Leader of the Year' Award at the UBM India Pharma Awards in 2016
Ms. Aditi Kare Panandikar receives the 'Businesswoman of the Year' award at the Business Goa Awards for Corporate Excellence in 2016
Ms. Aditi Kare Panandikar received the 2015 Jack L. Beal Post-baccalaureate Alumni Award from 'The Ohio State University College of Pharmacy' in USA
Goa Plant I Award
The Solid Dosage Forms and Externals Facility received the IDMA Quality Excellence Awards 2008 - Silver Award, for the third time.
The Solid Dosage Forms and Externals Facility received the IDMA Quality Excellence Awards 2003 - Formulations - Gold Award, second time since commissioned in 1997.
Goa Plant II Award
The Sterile Facility received the IDMA Quality Excellence Awards 2008 - Gold Award, for the third time.
The Sterile Facility for Injectibles and Ophthalmics received the IDMA Quality Excellence Awards 2003 - Formulations - Silver Award.
Milestone
1993
1997
1999
New Corporate Office at Indoco House
Acquisition of Warren. Indoco makes presence in Ophthalmic & Dental Segments
Turnover crosses Rs 100 crore
2002
2003
UK-MHRA approval for the Solid Dosage facility at Plant I
Exports to regulated markets commence
First contract for Dossier Development with European company
Domestic Marketing makes a foray into the lifestyle segment
2004
First Contract for Development services with US Company
Karvol brand acquisition from Solvay Pharmaceuticals Pvt. Ltd
Four Patent applications filed
Company jumps five ranks in two years in the ORG-IMS Retail Audit
2005
First ANDA filed on the basis of Exhibit batches manufactured in our sterile facility in Goa
Development Contracts for injectable products signed with a US Company
Tablet capacity doubled by commissioning an extended facility in the existing UK-MHRA approved plant
Shares of the Company listed on BSE and NSE
2006
US-FDA approval for Ophthalmic facility, Plant-II in GOA
Contract signed for supply of 18 generic products to German Market
2 ANDAs filed with USFDA
Commencement of liquid manufacturing facility at Baddi, Himachal Pradesh
New R&D Centre at Rabale, near Mumbai becomes functional
Solid Dosage facility at Goa Plant I re-inspected & approved by UK-MHRA
UK-MHRA approval for Creams & Ointments facility
Darmstadt-Germany approves our Goa facility for Solid Dosage manufacturing
Acquisition of LaNOVA Chem Pvt. Ltd. with its brand new API manufacturing facility of international standards
Launch of Surge - a specialty marketing division
2007
ANVISA (Brazil) approval for the Solid Dosage facility at GOA Plant I
Commencement of exports to the US markets
Launch of Warren-Excel and Spera - two specialty marketing divisions
2008
IDMA Quality Excellence Awards 2008 - The Sterile Facility at Goa Plant II received the Gold Award and the Solid Dosage Forms and Externals Facility at Goa Plant I received the Silver Award
TGA (Australia) approval for the Solid Dosage, Liquid Orals and Creams &Ointments Dosage forms at GOA Plant I
First shipment of Diclofenac Ophthalmic solution shipped to USA against an approved ANDA
Successfully faced Slovenia audit for the Solid Oral Dosage forms at Baddi Plant
MCC (South Africa) approval for the Solid Dosage facility at GOA Plant I and for the Sterile facility at Goa Plant II
2009
UK-MHRA approval for the Solid Oral Dosage forms at Baddi Plant
Export sales exceeded Rs. 1 Billion in the FY 08-09
Successfully faced Slovenia audit for the Sterile Facility at Goa Plant II for the Injections Area
2010
Indoco Remedies teams up with ASPEN, South Africa by licensing out intellectual property (dossiers) for marketing its products in emerging markets covering 30 countries, including SA, Brazil, Mexico, Venezuela, Russia & Australia
Indoco Remedies licenses out technology to Watson Pharmaceuticals Inc. USA. Under the terms of profit sharing agreement, Indoco will develop, manufacture and supply a basket of sterile products to Watson for the US market
2011
2012
Indoco announced the signing of an agreement with DSM, a € 9 billion Company, for commercial cooperation for Active Pharmaceutical Ingredients (APIs). Indoco and DSM have formed a strategic alliance, wherein DSM shall be marketing and selling the APIs manufactured by INDOCO
Innovation in Quality Award at CPhI Pharma Awards
2014
Inauguration of New GLP Analytical facility for Formulation
US-FDA approves Sterile (Plant II) and Solid Dosages (Plant III) facilities in Goa
IDMA Best Patent Award for Tazarotene & Adapalene
2015
2016
Indoco Honoured with the IDMA Best Patent Award for Three International Patents
Indoco achieves a milestone of Rs1000 crore
Indoco acquires Oral Solid Dosage manufacturing facility in Baddi from Micro Labs Ltd., Bangalore
Indoco's Allopurinol ANDA gets USFDA approval
Indoco climbs 187 ranks up - Fortune India
Indoco receives USFDA approval for solid dosages Plant I in Goa
Indoco honoured with the 'Best Patent Award' by PHARMEXCIL in the Bulk Drugs / API category
2017
Indoco receives the Express Pharma Export Excellence Award 2017
Indoco receives UKMHRA approval for solid dosages Plant I in Goa
Indoco receives the IDMA Best Patent Award for four API Process Patents
Indoco receives patent grant for Linezolid & Brinzolamide (FDFs) from United States Patent and Trademark Office (USPTO)
2018
Indoco commissions New API manufacturing facility at Patalganga
Indoco's Goa Plant II & III clears USFDA inspection
Indoco's API manufacturing facilities at Patalganga and Rabale successfully clear USFDA inspection
Indoco's API Patalganga site receives Renewed Accreditation Certificate from The Pharmaceuticals and Medical Devices Agency (PMDA), Japan
Indoco receives the IDMA Best Indian Patent Award for five API Process Patents
Indoco's Goa plant III receives EU GMP certification
2019
Indoco's Clinical Research Organisation receives zero 483s from USFDA
Indoco's stalwart brand CYCLOPAM crosses Rs 100 crore sales (as per IMS)
Indoco successfully completes UK-MHRA inspection at Goa Plant II
UK-MHRA reinstates full GMP status for Indoco's Goa Plant I
USFDA clears Indoco's Goa Plant II & III
Indoco gets European Patent Grant for unique process of Brinzolamide Eye Drops
Indoco wins the IDMA Formulations Patent Award 2017-18 for 2 International and 1 Indian patent
Indoco's new solid dosages facility at Baddi receives UK-MHRA approva
Indoco's Sterile Manufacturing Facility (Plant II) Clears USFDA Inspection
2020
Indoco receives USFDA approval for Apixaban Tablets 2.5 mg & 5 mg
Indoco awarded with the IDMA Formulations Best Patent Award 2018-19 for 2 formulation patents - Diclofenac & Quetiapine
Olopatadine ANDA filed from Indoco's Goa Plant II receives USFDA approval
AnaCipher Clinical Research receives BE study approval from WHO
First consignment of Glycopyrrolate Injection dispatched from Goa Plant II for launch in USA
Indoco receives USFDA approval for Succinylcholine Chloride Injection USP
Indoco receives USFDA approval for Olanzapine Tablets
Comment